RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

L. Paz-Ares; S. Senan; D. Planchard; L. Wang; A. Cheong; R. Slepetis; M. H. Nguyen; E. E. Vokes

RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

L. Paz-Ares, S. Senan, D. Planchard, L. Wang, A. Cheong, R. Slepetis, M. H. Nguyen, E. E. Vokes

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	67-67
Journal	Annals of Oncology
Volume	30
Publication status	Published - Apr 2019

Cite this

Paz-Ares, L., Senan, S., Planchard, D., Wang, L., Cheong, A., Slepetis, R., Nguyen, M. H., & Vokes, E. E. (2019). RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). Annals of Oncology, 30, 67-67.

Paz-Ares, L. ; Senan, S. ; Planchard, D. ; Wang, L. ; Cheong, A. ; Slepetis, R. ; Nguyen, M. H. ; Vokes, E. E. / RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). In: Annals of Oncology. 2019 ; Vol. 30. pp. 67-67.

@article{6295470acdce4d5eb13bdd87d49fb6d2,

title = "RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)",

author = "L. Paz-Ares and S. Senan and D. Planchard and L. Wang and A. Cheong and R. Slepetis and Nguyen, {M. H.} and Vokes, {E. E.}",

year = "2019",

month = apr,

language = "English",

volume = "30",

pages = "67--67",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Paz-Ares, L, Senan, S, Planchard, D, Wang, L, Cheong, A, Slepetis, R, Nguyen, MH & Vokes, EE 2019, 'RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)', Annals of Oncology, vol. 30, pp. 67-67.

RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). / Paz-Ares, L.; Senan, S.; Planchard, D.; Wang, L.; Cheong, A.; Slepetis, R.; Nguyen, M. H.; Vokes, E. E.

In: Annals of Oncology, Vol. 30, 04.2019, p. 67-67.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

AU - Paz-Ares, L.

AU - Senan, S.

AU - Planchard, D.

AU - Wang, L.

AU - Cheong, A.

AU - Slepetis, R.

AU - Nguyen, M. H.

AU - Vokes, E. E.

PY - 2019/4

Y1 - 2019/4

M3 - Meeting Abstract

VL - 30

SP - 67

EP - 67

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -